BofA and TD Cowen Cut Marvell to Neutral After $115B Lumentum Deal

BofA cut Marvell Technology (NASDAQ:MRVL) to Neutral from Buy and slashed its price target to $225 from $400 after the chipmaker agreed to acquire Lumentum in an all-stock deal valued at roughly $115 billion including debt. TD Cowen followed within the same news cycle, downgrading Marvell to Hold from Buy and trimming its target to $175 from $350.

The market's verdict was immediate. Marvell shares fell roughly 13% after the announcement, per the source analysis. Investors are discounting execution risk, dilution and the possibility that Marvell is overpaying for optical exposure while AI infrastructure valuations remain stretched.

What does the deal actually buy Marvell?

The strategic logic is straightforward. Marvell designs the chips and networking gear that move data inside AI data centers. Lumentum makes optical components that carry that data as light. Combining the two would give Marvell a broader position in the optical connectivity layer of AI infrastructure — an area that could grow in importance as AI clusters expand and data movement becomes a bigger bottleneck.

In that reading, the acquisition lets Marvell capture a larger share of AI-related spending instead of staying concentrated in its existing chip and networking footprint.

Why did the financing structure spook investors?

The skepticism centers on how Marvell is paying. Because the deal is all-stock, current shareholders will own a smaller slice of a larger company. That dilution matters especially when the market hasn't yet seen how the two product lines fit together.

The 13% share drop signals investors are pricing in three risks at once: dilution, integration complexity and a potentially rich price for optical assets.

Are all analysts bearish?

No. UBS reiterated its Buy rating and $350 target on November 3, signaling that at least one major firm still sees the combination as strategically compelling. Cantor Fitzgerald held at Neutral but lowered its target to $225.

That split is instructive. Analysts are weighing whether the optical business gives Marvell a meaningfully bigger slice of AI spending against whether the deal adds integration risk, complicates the product roadmap and dilutes existing holders before benefits become visible.

Was the skepticism there before the deal?

Largely, yes. The skeptics' case predates the announcement. As previously laid out, the few analysts without a Buy rating were already focused on valuation, execution and the durability of Marvell's AI growth outlook weeks before Lumentum entered the picture. The deal didn't create that debate — it sharpened it.

The bull case: optics expand Marvell's AI opportunity. The bear case: dilution and integration risk arrive before the payoff is proven.

What comes next for the integration?

Investors will watch how the two companies combine product lines. Marvell's strengths in data-center chips and networking gear must mesh with Lumentum's optical components to produce real cross-selling or bundled offerings — not just a larger, more complex company.

The execution test arrives while the Street is openly divided. With BofA at $225, TD Cowen at $175, Cantor Fitzgerald at $225 and UBS at $350, the target spread itself shows how much the market's view of Marvell's AI franchise now hinges on making the Lumentum combination work.